Head-to-Head: which new heart valve is best for aortic stenosis?

NCT ID NCT07545369

Not yet recruiting Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two latest-generation heart valves (SAPIEN 3 Ultra Resilia and Evolut FX) in 200 patients with severe aortic stenosis. Participants will be randomly assigned to receive one valve during a standard procedure and followed for one year. The goal is to see which valve works better and has fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAPIEN 3 Ultra Resilia and Evolut FX transcatheter aortic valves
What this could lead to: If successful, this could show which valve type works better for patients with severe aortic stenosis, helping doctors choose the best option.
What could go wrong: This is a small, early-stage trial with only 200 participants, so results may not apply to all patients. Both valves are already approved, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE AORTIC VALVE STENOSIS

Contacts and locations

Locations

Assiut University Heart Hospital

Asyut, Assiut Governorate, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.